Drugs, Investigational
-
Subject Areas on Research
- A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.
- A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
- A review of three-dimensional in vitro tissue models for drug discovery and transport studies.
- AZD6140.
- Aptamers: an emerging class of therapeutics.
- Bioelectronic medicines: a research roadmap.
- Clinical results in cachexia therapeutics.
- Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.
- Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
- Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
- Emerging drugs for attention-deficit/hyperactivity disorder.
- Emerging drugs for diabetic retinopathy.
- Emerging echinocandins for treatment of invasive fungal infections.
- Ethical issues in umbilical cord blood banking. Working Group on Ethical Issues in Umbilical Cord Blood Banking.
- Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow.
- Extraordinary claims require extraordinary evidence.
- Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
- Informed consent and investigational new drug abuses in the U.S. military.
- Inhibitors of platelet adhesion.
- Investigational dopamine antagonists for the treatment of schizophrenia.
- Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.
- Lessons learned from a clinical trial.
- New FDA breakthrough-drug category--implications for patients.
- New antifungal agents.
- Novel medication targets for the treatment of alcoholism: preclinical studies.
- On power and sample size calculation for QT studies with recording replicates at given time point.
- Phase II cancer clinical trials with heterogeneous patient populations.
- Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.
- Prasugrel.
- Proposals of statistical consideration to evaluation of results for a specific region in multi-regional trials--Asian perspective.
- QT as a safety biomarker in drug development.
- Returns to R&D on new drug introductions in the 1980s.
- Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
- Statistical inference for cancer trials with treatment switching.
- Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience.
- Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.
- The Food and Drug Administration and pragmatic clinical trials of marketed medical products.
- The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.
- The distribution of sales revenues from pharmaceutical innovation.
- The nonapproved use of medications.
- The price of innovation: new estimates of drug development costs.
- The quantity and quality of worldwide new drug introductions, 1982-2003.
- Update on the management of hyperuricemia and gout.
- Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
- Who should go first in trials with scarce agents? The views of potential participants.